What is it about?
Subcutaneous extended-release buprenorphine appeared to be as feasible during pregnancy as oral buprenorphine-based treatments in this initial study. Steady drug concentration may enhance treatment adherence and improve pregnant individuals’ health, benefiting the well-being of newborns and reducing neonatal withdrawal symptoms.
Featured Image
Photo by Hu Chen on Unsplash
Why is it important?
Opioid maintenance therapy is recommended during pregnancy, but carries risks. Therefore, knowledge of the safety profiles of pharmacotherapy options is necessary.
Perspectives
After observing the positive clinical outcomes of mothers receiving extended-release buprenorphine treatment and their healthy newborns, I am delighted to present this article.
Minna Kanervo
University of Helsinki
Read the Original
This page is a summary of: Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes, European Journal of Obstetrics & Gynecology and Reproductive Biology, June 2024, Elsevier,
DOI: 10.1016/j.ejogrb.2024.04.003.
You can read the full text:
Contributors
The following have contributed to this page
